Dermaroller treatment for hair loss has gained considerable attention as a potential adjunct to established therapies such as minoxidil. The technique — formally known as microneedling or collagen induction therapy — involves rolling a device fitted with fine needles across the scalp to create controlled micro-injuries, which may stimulate hair follicle activity and enhance topical absorption. While early clinical evidence is encouraging, particularly for androgenetic alopecia, the treatment is not yet formally endorsed by NICE or NHS pathways. This article explains how dermarolling works, what the evidence shows, which hair loss types may respond, and how to use the device safely.

What Is Dermaroller Treatment and How Does It Work?

A dermaroller creates microscopic scalp punctures that trigger wound-healing responses, releasing growth factors that may activate hair follicles and temporarily increase skin permeability to enhance topical treatment absorption.

A dermaroller is a handheld device fitted with a cylindrical drum covered in fine, short needles — typically ranging from 0.25 mm to 1.5 mm in length. When rolled across the skin or scalp, these needles create thousands of microscopic punctures in the upper layers of tissue. This controlled micro-injury triggers the body's natural wound-healing response, stimulating the production of collagen, elastin, and growth factors. The technique is formally known as microneedling or collagen induction therapy.

In the context of hair loss, the mechanism of action is not fully understood, but several overlapping biological pathways have been proposed. It is hypothesised that micro-injuries stimulate the release of platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF), and may influence Wnt signalling proteins — all of which have been implicated in hair follicle biology in laboratory and early clinical studies. These pathways may play a role in activating dormant hair follicles and influencing the anagen (growth) phase of the hair cycle, though the clinical significance of these effects in humans remains under investigation. Microneedling may also transiently increase scalp skin permeability, which could enhance the absorption of topical treatments applied after the procedure — though this also carries implications for increased absorption of any product applied, including potential adverse effects (see below).

Experiencing these side effects? Our pharmacists can help you navigate them →

Dermarollers used at home typically feature needle lengths of 0.25–0.5 mm, which are generally considered lower risk for self-use, though the optimal needle length and technique for the scalp have not been standardised and should ideally be guided by a clinician. Longer needles (0.5–1.5 mm) are generally reserved for clinical settings, where a trained practitioner can ensure appropriate technique, sterility, and aftercare. It is important to distinguish between at-home dermarollers and professional microneedling devices, as the depth of penetration, precision, and associated risks differ considerably between the two.

From a regulatory standpoint, microneedling devices intended to penetrate the skin or make medical claims are classified as medical devices in the UK and should carry UKCA or CE marking. Patients should check that any device they purchase meets these requirements. If you are unsure whether a product is appropriately regulated, the MHRA's guidance on medical device classification provides further information.

Evidence for Dermarolling as a Hair Loss Treatment

Small RCTs suggest microneedling combined with minoxidil improves hair counts more than minoxidil alone, but NICE does not formally recommend it and evidence remains limited by small cohort sizes and short follow-up periods.

The evidence base for microneedling as a hair loss treatment is growing, though it remains relatively limited compared to established therapies such as minoxidil or finasteride. Several small-scale randomised controlled trials (RCTs) have produced encouraging results, particularly for androgenetic alopecia (male and female pattern hair loss).

Not sure if this is normal? Chat with one of our pharmacists →

A frequently cited study published in the Journal of Cutaneous and Aesthetic Surgery (Dhurat et al., 2013) compared weekly microneedling combined with minoxidil against minoxidil alone in men with androgenetic alopecia. The microneedling group demonstrated significantly greater hair count improvement at 12 weeks, suggesting a possible synergistic effect. More recent systematic reviews and meta-analyses (published 2021–2023) have broadly supported these findings but consistently highlight that most included studies involve small cohorts, short follow-up periods, and considerable methodological heterogeneity, making firm conclusions difficult.

Evidence in women with female pattern hair loss is more limited, and data in alopecia areata are heterogeneous and preliminary. Microneedling for these conditions should only be considered as an adjunct within specialist-guided care.

At present, microneedling for hair loss is not formally recommended by NICE, and it does not appear in NHS treatment pathways for alopecia. No specific dermaroller device has been licensed or approved as a medical treatment for hair loss in the UK; relevant devices require UKCA or CE marking and must not make unsubstantiated medical claims. This does not mean the treatment is ineffective, but it does mean that the evidence has not yet met the threshold required for formal clinical endorsement. Patients should be aware that:

• Most studies involve small cohorts and lack long-term follow-up data

• Results vary considerably between individuals

• The optimal needle length, frequency, and technique have not been standardised

• Evidence is strongest for androgenetic alopecia; data for other hair loss types are more limited

Further large-scale, well-controlled trials are needed before definitive conclusions can be drawn. In the meantime, dermarolling may be considered a complementary approach rather than a standalone treatment, and should be discussed with a GP or dermatologist before starting.

Which Types of Hair Loss May Respond to Dermarolling?

Androgenetic alopecia has the strongest supporting evidence; dermarolling is generally unsuitable for scarring alopecias, active scalp infections, telogen effluvium, and several medical conditions including anticoagulant use.

Not all forms of hair loss are likely to respond equally to dermaroller treatment. The strongest evidence currently exists for androgenetic alopecia (pattern baldness), which affects both men and women and is driven by genetic sensitivity to dihydrotestosterone (DHT). In this condition, hair follicles gradually miniaturise over time, and microneedling may help reactivate follicles that are dormant but not yet permanently lost — though this remains a hypothesis based on limited clinical data.

There is some emerging, but inconsistent, evidence for the use of microneedling in alopecia areata, an autoimmune condition causing patchy hair loss. A small number of studies suggest that microneedling may modulate local immune responses and stimulate regrowth in affected patches. However, there is also a theoretical risk of the Koebner phenomenon — whereby trauma to the skin triggers new lesions — and microneedling should not replace established first-line treatments such as potent topical corticosteroids, intralesional corticosteroid injections, or immunotherapy. Any use in alopecia areata should be specialist-led. Further information on recommended treatments is available via NICE CKS: Alopecia areata and the British Association of Dermatologists (BAD) patient information leaflets.

Telogen effluvium — diffuse shedding triggered by illness, nutritional deficiency, stress, or hormonal change (including postpartum hair loss) — is unlikely to benefit from microneedling. The underlying cause should be identified and addressed first.

Dermarolling is generally considered less appropriate or potentially harmful in the following situations:

• Scarring alopecias (e.g., lichen planopilaris, frontal fibrosing alopecia) — where follicles are permanently destroyed and inflammation may be worsened

• Active scalp infections, including tinea capitis (scalp ringworm) or folliculitis

• Open wounds, psoriasis plaques, or eczema affecting the scalp

• Anticoagulant or antiplatelet therapy (e.g., warfarin, apixaban, clopidogrel) or bleeding disorders that increase bleeding risk

• Recent or current isotretinoin use — microneedling is generally contraindicated during isotretinoin treatment and for at least six months after stopping, due to impaired wound healing

• Immunosuppression (whether due to medication or underlying condition)

• Uncontrolled diabetes — impaired healing increases infection risk

• Children and young people — microneedling is not recommended in paediatric patients

• Pregnancy and breastfeeding — particularly if combining with minoxidil, which is contraindicated in these groups

Individuals who are uncertain about the underlying cause of their hair loss should seek a diagnosis from their GP or a dermatologist before attempting any form of microneedling. The Primary Care Dermatology Society (PCDS) and BAD provide UK-specific guidance on diagnosis and referral. Treating the wrong type of alopecia could delay appropriate care or cause harm.

How to Use a Dermaroller Safely on the Scalp

Use a 0.25–0.5 mm needle device on a clean, dry scalp, disinfect before and after each session, apply no topical treatments for at least 24 hours post-procedure, and limit use to once weekly.

If you have confirmed androgenetic alopecia and have discussed microneedling with a healthcare professional, using a dermaroller at home requires careful attention to hygiene, technique, and frequency. Incorrect use is one of the most common reasons for adverse outcomes.

Before you begin:

• Choose a dermaroller with a needle length of 0.25–0.5 mm for home use; follow your clinician's advice and the manufacturer's instructions for use (IFU)

• Disinfect the device before and after each use with 70% isopropyl alcohol (note: this reduces the number of micro-organisms on the device but does not achieve full sterilisation)

• Dermarollers are single-user devices — never share a device with another person, due to the risk of transmitting blood-borne infections

• Wash your hands thoroughly and ensure the scalp is clean and dry

• Do not use the device on broken, irritated, or sunburnt skin

• Inspect the needles before each use; stop using the device if needles appear bent, blunted, or damaged, as this increases the risk of uneven injury and infection

Technique: Divide the scalp into sections and roll the device gently in horizontal, vertical, and diagonal directions over each area — typically four to six passes per direction. Apply light, even pressure; the device should not cause significant pain or bleeding. Stop immediately if you experience sharp pain or more than very minor pinpoint bleeding.

After treatment: The scalp skin barrier is temporarily disrupted following microneedling. For this reason:

• Avoid applying minoxidil or other topical treatments until the scalp has fully recovered — generally at least 24 hours after the procedure and only once any redness or tenderness has resolved. Applying minoxidil to irritated or damaged skin is not recommended and may increase the risk of local irritation and systemic absorption (see the UK Summary of Product Characteristics [SmPC] for your minoxidil product, available via the electronic Medicines Compendium [eMC]). If you use a minoxidil solution, be aware that most contain alcohol, which may cause additional irritation to a compromised skin barrier; an alcohol-free foam formulation may be preferable — discuss this with your clinician

• Avoid products containing retinoids or strong acids immediately after treatment

• Avoid swimming, saunas, heavy exercise, hair dye, chemical treatments, and direct UV exposure for at least 24–48 hours after each session

Frequency: The optimal frequency for home microneedling has not been standardised in clinical trials. Once weekly is a commonly cited interval for home use, but you should follow your clinician's advice and the device IFU. More frequent use does not improve outcomes and may impair the skin's ability to heal adequately between sessions. Replace the device when needles show signs of wear or damage; follow the manufacturer's guidance on replacement intervals.

Possible Side Effects and Risks to Be Aware Of

Common effects include temporary redness and scalp sensitivity; more serious risks include infection, increased systemic absorption of topical minoxidil, post-inflammatory hyperpigmentation, and worsening of underlying scalp conditions.

Dermaroller treatment is generally well tolerated when used correctly, but it is not without risk. Understanding the potential side effects helps individuals make an informed decision and recognise when to seek medical advice.

Common, expected effects following treatment include:

• Mild redness and scalp sensitivity lasting a few hours

• Slight swelling or a warm sensation in the treated area

• Minor pinpoint bleeding, particularly with longer needle lengths

These effects typically resolve within 24–48 hours and are considered part of the normal healing response.

Less common but more serious risks include:

• Infection — the most significant concern with at-home use. Inadequate disinfection of the device, sharing devices, or poor scalp hygiene can introduce bacteria into the micro-channels, potentially causing folliculitis or cellulitis

• Increased absorption of topical products — because microneedling temporarily increases skin permeability, any topical agent applied afterwards (including minoxidil) may be absorbed at higher levels than usual. This could increase the risk of local irritation and, in the case of minoxidil, systemic effects such as dizziness, headache, or palpitations. Stop using any topical product and seek medical advice if you experience these symptoms

• Post-inflammatory hyperpigmentation — more common in individuals with darker skin tones

• Scarring — rare but possible if excessive pressure is applied or the skin is not given adequate time to heal between sessions

• Worsening of underlying scalp conditions — particularly in inflammatory or scarring alopecias

When to contact your GP or seek medical advice:

• Signs of infection such as increasing redness, warmth, swelling, pus, or fever

• Unusual or worsening hair loss following treatment

• Persistent pain or scalp irritation beyond 48 hours

• Any new skin changes in the treated area

• Systemic symptoms such as dizziness, palpitations, or headache after applying topical treatments post-procedure

• Hair loss in children, rapidly progressive or diffuse shedding, scalp pain or scarring, loss of eyebrows or eyelashes, or any associated systemic symptoms — these warrant prompt GP or dermatology review

Long-term safety data for home microneedling of the scalp are limited. If you experience a suspected side effect or a problem with a device, you can report this to the MHRA via the Yellow Card scheme (yellowcard.mhra.gov.uk). This applies to both device-related issues and any suspected adverse reactions to medicines used alongside the procedure. Anyone with a history of keloid scarring, blood disorders, or immunosuppression should consult a dermatologist before proceeding.

Frequently Asked Questions